4,5-dihydro-1,2,4-triazolo[1,5-a]quinoxalin-4-ones: Excitatory amino acid antagonists with combined glycine/NMDA and AMPA receptor affinity

Journal of Medicinal Chemistry

Volumn 42, Issue 13, 1999, Pages 2478-2484

  Catarzi, Daniela ^a   Colotta, Vittoria ^a   Varano, Flavia ^a   Cecchi, Lucia ^a   Filacchioni, Guido ^a   Galli, Alessandro ^a   Costagli, Chiara ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID RECEPTOR BLOCKING AGENT; AMPA RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL TISSUE; ARTICLE; BINDING SITE; CHEMICAL STRUCTURE; CONTROLLED STUDY; MOLECULAR RECOGNITION; NONHUMAN; RAT; RECEPTOR AFFINITY; RECEPTOR BINDING; SYNTHESIS;

ANIMALS; BINDING, COMPETITIVE; EXCITATORY AMINO ACID ANTAGONISTS; ION CHANNELS; LIGANDS; QUINOXALINES; RECEPTORS, AMPA; RECEPTORS, GLYCINE; RECEPTORS, N-METHYL-D-ASPARTATE; STRUCTURE-ACTIVITY RELATIONSHIP; SYNAPTIC MEMBRANES;

EID: 0033168950     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm981102r     Document Type: Article

References (30)

1. Monaghan, D. T.; Bridges, R. J.; Cotman, C. W. The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu. Rev. Pharmacol. Toxicol. 1989, 29, 365-402.
2. Hollmann, M.; Heinemann, S. Cloned glutamate receptors. Annu. Rev. Neurosci. 1994, 17, 31-108.
3. Watkins, J. C.; Krogsgaard-Larsen, P.; Honore, T. Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists. Trends Pharmacol. Sci, 1990, 11, 25-33.
4. Johnson, J. W.; Ascher, P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 1987, 325, 529-531.
5. Arias, R. L.; Tasse, J. R. P.; Bowlby, M. R. Neuroprotective interaction effects of NMDA and AMPA receptor antagonists in an in vivo model of cerebral ischemia, Brain Res. 1999, 816, 299-308.
6. Lippert, K.; Welsch, M.; Krieglstein, J. Over-additive protective effect of dizocilpine and NBQX against neuronal damage. Eur. J. Pharmacol. 1994, 253, 207-213.
7. Löscher, W.; Rundfeldt, C.; Hönack, D. Low doses of NMDA receptor antagonists synergistically increase the anticonvulsant effect of the AMPA receptor antagonist NBQX in the Kindling model of epilepsy. Eur. J. Neurosci. 1993, 5, 1545-1550.
8. Löscher, W.; Hönack, D. Over-additive anticonvulsant effect of memantine and NBQX in kindled rats. Eur. J. Pharmacol. 1994, 259, R3-R5.
9. Bigge, C. F.; Malone, T. C.; Boxer, P. A.; Nelson, C. B.; Ortwine, D. F.; Schelkun, R. M.; Retz, D. M.; Lesosky, L. J.; Borosky, S. A.; Vartanian, M. G.; Schwarz, R. D.; Campbell, G. W.; Robichaud, L. J.; Watjen, F. Synthesis of 1,4,7,8,9,10-hexahydro-9-methyl-6-nitropyrido[3,4-f]quinoxaline-2,3-dione and related quinoxalinediones: characterization of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (and N-methyl-D-aspartate) receptor and anticonvulsant activity. J. Med. Chem. 1995, 38, 3720-3740.
10. Mosinger, J. L.; Price, M. T.; Bai, H. Y.; Xiao, H.; Wozniak, D. F.; Olney, J. W. Blockade of both NMDA and non-NMDA receptors is required for optimal protection against ischemic neuronal degeneration in the in vivo adult mammalian retina. Exp. Neurol. 1991, 113, 10-17.
11. Carling, R. W.; Leeson, P. D.; Mooree, K. W.; Smith, J. D.; Moyes, C. R.; Mawer, I. W.; Thomas, S.; Chan, T.; Baker, R.; Foster, A. C.; Grimwood, S.; Kemp, J. A.; Marshall, G. R.; Tricklebank, M. D.; Saywood, K. L. 3-Nitro-3,4-dihydro-2(1H)-quinolines. Excitatory amino acid antagonists acting at the glycine-site of the NMDA and (RS)-AMPA receptors. J. Med. Chem. 1993, 36, 3397-3408.
12. Leeson, P. D.; Iversen, L. L. The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential. J. Med. Chem. 1994, 37, 4053-4067.
13. Kulagowski, J. J. Glycine-site NMDA receptor antagonists: an update. Exp. Opin. Ther. Patents 1996, 6, 1069-1079.
14. Bigge, C. F.; Nikam, S. S. AMPA receptor agonists, antagonists and modulators: their potential for clinical utility. Exp. Opin. Ther. Patents 1997, 7, 1099-1114.
15. Cai, S. X.; Kher, S. M.; Zhou, Z.-L.; Ilyin, V.; Espitia, S. A.; Tran, M.; Hawkinson, J. E.; Woodward, R. M.; Weber, E.; Keana, J. F. W. Structure-activity relationships of alkyl- and alkoxy-substituted 1,4-dihydroquinoxaline-2,3-diones: potent and sistematically active antagonists for glycine site of the NMDA receptor. J. Med. Chem. 1997, 40, 730-738.
16. Auberson, Y. P.; Bischoff, S.; Moretti, R.; Schmutz, M.; Veenstra, S. J. 5-Aminomethylquinoxaline-2,3-diones. Part I: a novel class of AMPA receptor antagonists. Bioorg. Med. Chem. Lett. 1998, 8, 65-70.
17. Acklin, P.; Allgeier, H.; Auberson, Y. P.; Bischoff, S.; Ofner, S.; Sauer, D.; Schmutz, M. 5-Aminomethylquinoxaline-2,3-diones, Part III: arylamide derivatives as highly potent and selective glycine-site NMDA receptor anatagonists. Bioorg. Med. Chem. Lett. 1998, 8, 493-498.
18. Catarzi, D.; Cecchi, L.; Colotta, V.; Melani, F.; Filacchioni, G.; Martini, C.; Giusti, L.; Lucacchini, A. Tricyclic heteroaromatic systems. 1,2,4-Triazolo[1,5-a]quinoxalines: synthesis and benzodiazepine receptor activity. Farmaco 1993, 48, 1065-1078.
19. Catarzi, D.; Cecchi, L.; Colotta, V.; Filacchioni, G.; Melani, F. Tricyclic heteroaromatic systems. 1,2,4-TriazoIo[1,5-a]quinoxaline. J. Heterocycl. Chem. 1992, 29, 1161-1163.
20. Nagata, R.; Tanno, N.; Kodo, T.; Ae, N.; Yamaguchi, H.; Nishimura, T.; Antoku, F.; Tatsuno, T.; Kato, T.; Tanaka, Y.; Nakamura, M.; Ogita, K.; Yoneda, Y. Tricyclic quinoxalinediones: 5,6-dihydro-1H-pyrrolo[1,2,3-de]quinoxaline-2,3-diones and 6,7-dihydro-1H,5H-pyrido[1,2,3-de]quinoxaline-2,3-diones as potent antagonists for the glycine binding site of the NMDA receptor. J. Med. Chem. 1994, 37, 3956-3968.
21. Wong, E. H. F.; Kemp, J. A.; Priestley, T.; Knight, A. R.; Woodruff, G. N.; Iverson, L. L. The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 7104-7108.
22. 3H]MK-801 binding to the NMDA receptor in rat brain. Eur. J. Pharmacol. 1987, 142, 487-488.
23. Fusco, R.; Rossi, S. New synthesis of benzo(1,2,4)triazine moiety. Gazz. Chim. Ital. 1956, 86, 484-499.
24. Andersson, B.; Lamm, B. Studies in nucleophilic aromatic substitution reactions. Acta Chem. Scand. 1969, 23, 2983-2988.
25. Brunton, J. C.; Suschitzky, H. Decomposition of mixed diazonium fluoborates. J. Chem. Soc. 1955, 1035.
26. Colotta, V.; Catarzi, D.; Varano, F.; Cecchi, L.; Filacchioni, G.; Galli, A.; Costagli, C. Synthesis and biological evaluation of a series of quinazoline-2-carboxylic acids and quinazoline-2,4-diones as glycine-NMDA antagonists: a pharmacophore model based approach. Arch. Pharm. Pharm. Med. Chem. 1997, 330, 129-134.
27. Nielsen, E. O.; Madsen, U.; Schaumburg, K.; Brehm, L.; Krogsgaard-Larsen, P. Studies on receptor-active conformations of excitatory amino acid agonists and antagonists. Eur. J. Chem.-Chim. Ther. 1986, 21, 433-437.
28. Yoneda, Y.; Ogita, K.; Suzuku, T. Interaction of strychnine-insensitive glycine binding with MK-801 in brain synaptic membranes. J. Neurochem. 1990, 55, 237-244.
29. De Lean, A.; Munson, P. J.; Rodbard, D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radio-ligand assay and physiological dose-response curves. Am. J. Physiol. 1978, 235, E97-102.
30. 50) of an enzimatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.